The invention pertains to a novel cell line, an HIV tat-rev dependent GFP-Gaussia luciferase Reporter cell line, known henceforth as the GGR cell line, that detects pseudotype and replication competent HIV (cloned or uncloned isolates, in cell media or human serum) rapidly and with high sensitivity. This GGR cell line provides an improved method of characterizing the entry phenotype of HIV envelope genes, and detecting and examining primary HIV samples in the context of laboratory research, clinical trial monitoring, and medical diagnostics. Examples include, but are not limited to, determining the functional HIV viral load, responsiveness to treatment, characterization of viral co-receptor usage (testing for viral co-receptor usage, i.e., CCR5 vs CXCR4, as required prior to prescribing FDA-approved CCR5 inhibitors), and characterization of other viral or drug resistance phenotypic properties to guide treatment.

The oligonucleotide of sequence SEQ ID No.1: 5′-CTAGAGATCCCTCAGA-3′, and the complementary sequence thereof of sequence SEQ ID No.2: 5′-TCTGAGGGATCTCTAG-3′ useful as probes to detect and quantify all HIV-1 circulating forms and their precursors SIVcpz/SIVgor.

Disclosed are synthetic 71 base pair, partially-double stranded DNA oligonucleotides and methods for their use in the amplification and identification or integrated proviral DNA.

The present invention provides a method of identifying a cell latently infected with HIV, wherein the method comprises: providing a sample of cells; encapsulating individual cells in droplets; screening for the presence of HIV derived DNA in the genomic DNA of encapsulated cells; and identifying, and optionally isolating, cells containing latent HIV derived DNA.

Provided are methods for predicting effectiveness of vaccine against HIV or SIV. Provided herein also are methods for predicting protective immunity in a subject, comprising detecting expression levels of multiple genes or gene products, wherein the multiple genes have been identified as a differentially expressed gene set associated with protective immunity against HIV or SIV; calculating a first composite gene expression score (GES) for the differentially expressed gene set; and calculating an average second composite GES for the differentially expressed gene set in biological samples from subjects that have been vaccinated with a candidate vaccine and are not immune to the virus, wherein a first composite GES that is greater than the average second composite GES indicates the effectiveness of the vaccine and that the subject has protective immunity. Also provided are kits for predicting effectiveness of HIV or SIV vaccine and for predicting protective immunity following vaccination.

A multi-layer plasma separation card comprising (a) a first layer including a sample receiving member comprising (i) a top planar surface for applying or receiving a blood sample, said sample receiving portion being adapted to permit contact of said blood sample with a separating member; and (ii) a bottom planar surface being adapted to contact said separating member, (b) a second layer including at least three separating members, each separating member being adapted to permit the passage of plasma to an absorptive member and comprising (i) a top planar surface for receiving said blood sample; and (ii) a bottom planar shield-shaped surface being adapted to contact said absorptive member, and (c) a third layer including at least two absorptive members for absorbing plasma from the bottom planar surface of each corresponding separating member and a backing member arranged in a manner to support said absorptive members, each absorptive member comprising a removable absorptive element having a top planar surface being adapted to contact said bottom planar surface of the separating member, said absorptive element is detachable fixed to the third layer.

Provided are methods for identifying patient populations infected with HIV that can be targeted by antibodies that bind to HIV gp120 CD4 binding site (CD4bs) region.

The present invention relates to a low-cost, thermally reversible valve for paper-fluidic diagnostic devices. In particular, this invention demonstrates a tunable valve mechanism fabricated by wax-ink printing and localized heating via thin-film resistors to sequentially release liquids through a cellulose or nitrocellulose membrane. The wax-ink valve can obstruct fluid flow for a sustained time and are thermally actuated to release a controlled amount of liquid past the valve. This integrated paper-fluidic diagnostic assay device requires minimal user involvement, can be easily manufactured and tuned to meet various fluid delivery timing and incubation needs.

This application describes a fluorogenic nucleic acid kit or composition for quantitative detection of a target ribonucleic acid (RNA) sequence in a test sample comprising at least one pair of oligonucleotide probes comprising a photocatalyst probe and a profluorophore probe, wherein one of the photocatalyst probe and the profluorophore probe is complementary to and capable of specifically binding an upstream portion of the target RNA sequence, and the other probe is complementary to and capable of specifically binding to a downstream portion of the target RNA sequence, the photocatalyst probe comprises a first oligonucleotide covalently bound to a photocatalyst, the profluorophore probe comprises a second oligonucleotide covalently bound to a profluorophore, and the photocatalyst is activatable by exposure to light and a reducing agent to form a reduced, activated photocatalyst that, when both probes of the pair are hybridized to the target RNA sequence, is capable of photoreducing the profluorophore to form a detectable fluorophore. The application also describes methods for quantitative detection of target RNA.

The present disclosure relates to high-throughput systems and methods for the detection of ligand-blocking antibodies and for determining antibody potency.